SUPN

SUPERNUS PHARMACEUTICALS, INC.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001356576
$44.41 -2.50% $2.6B
Insider Selling Cluster (7 insiders)High Impact Filing (7/10)18 New Institutional Positions10 Institutional Exits
Vol
Market Cap$2.6B
Cap SizeMid Cap
Inst. Holders50 funds
Inst. Value$2.0B
Inst. Activity18 buys / 10 sells
Insider Activity0B / 10S
Insider Net $-$6.5M
SEC Reports8
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001356576·Prev Close $45.55

Recent Activity

Jun 11, 2026 SEC
Institutional cluster for SUPN shows mixed activity in Q4 2025: three buyers (Wells Fargo, Morgan Stanley, Point72) adde
INST-CLUSTER — Impact 3/10
May 20, 2026 SEC
Supernus notified the CVR rights agent that Milestone 1 was achieved on March 18, 2026, triggering a $0.50-per-CVR cash
8-K — Impact 3/10
Apr 22, 2026 SEC
Supernus Pharmaceuticals announced it will report its Q1 2026 financial results on May 5, 2026, after market close. This
8-K — Impact 2/10
Mar 18, 2026 Insider
Bhatt Padmanabh P. acquired via exercise 7,250 shares
Sr. VP of IP, CSO @ $39.40 ($285.6K)
Mar 18, 2026 Insider
Bhatt Padmanabh P. sold 6,838 shares
Sr. VP of IP, CSO @ $49.55 ($338.8K)
Mar 17, 2026 Insider
Bhatt Padmanabh P. acquired via exercise 22,750 shares
Sr. VP of IP, CSO @ $39.40 ($896.4K)
Inst.
Point72 Asset Management, L.P. — TRIM
1,318,555 shares ($68.2M)
Inst.
BANK OF AMERICA CORP — ADD
714,226 shares ($36.9M)

Price Targets

Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$62.83 (Dec 2025)
Current $44.41 Low $55.00 Median $64.00 High $66.00 6 analysts
$55.00 $66.00

Analyst Ratings

Historical distribution83% buy · 12 analysts · last covering-analyst action Dec 2025
4Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
DateFirmActionRating
Dec 19, 2025 Stifel MAINTAIN Hold → Hold

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.46 ▼ -16.5% $0.44 — $0.47 -50% YoY 2
Next Q $0.67 ▼ -7.4% $0.59 — $0.75 10% YoY 3
Current FY $2.49 ▲ +6.3% $2.11 — $2.95 4% YoY 3
Next FY $4.34 ▲ +2.9% $3.77 — $4.76 75% YoY 3

Latest Reports

NEUTRAL INST-CLUSTER 3/10
Institutional cluster for SUPN shows mixed activity in Q4 2025: three buyers (Wells Fargo, Morgan Stanley, Point72) adde
Jun 11, 2026
NEUTRAL 8-K 3/10
Supernus notified the CVR rights agent that Milestone 1 was achieved on March 18, 2026, triggering a $0.50-per-CVR cash
May 20, 2026

Top Institutional Holders

FundValueMove
BlackRock, Inc.$454.7M—
VANGUARD PORTFOLIO MANAGEMENT LLC$167.4M—
VANGUARD CAPITAL MANAGEMENT LLC$127.5M—
DIMENSIONAL FUND ADVISORS LP$119.2M—
STATE STREET CORP$118.3M—

Recent Insider Trades

DateInsiderTypeValue
Mar 18, 2026Bhatt PadmanabhM$285.6K
Mar 18, 2026Bhatt PadmanabhSELL$338.8K
Mar 17, 2026Bhatt PadmanabhM$896.4K
Mar 17, 2026Bhatt PadmanabhSELL$1.4M
Mar 16, 2026Bhatt PadmanabhM$836.1K
50 institutional holders with $2.0B total value (38,179,878 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, VANGUARD. Net buying activity: 18 institutions added/increased vs 10 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1BlackRock, Inc.8,797,254$454.7M23.1%—
2VANGUARD PORTFOLIO MANAGEMENT LLC3,238,693$167.4M8.5%—
3VANGUARD CAPITAL MANAGEMENT LLC2,467,215$127.5M6.5%—
4DIMENSIONAL FUND ADVISORS LP2,307,030$119.2M6.0%—
5STATE STREET CORP2,288,127$118.3M6.0%—
6NOMURA ASSET MANAGEMENT INTERNATIONAL INC.2,037,202$105.3M5.3%—
7RENAISSANCE TECHNOLOGIES LLC1,705,222$88.1M4.5%—
8CITADEL ADVISORS LLC1,493,446$77.2M3.9%—
9LOOMIS SAYLES & CO L P1,425,779$73.7M3.7%—
10Point72 Asset Management, L.P.1,318,555$68.2M3.5%TRIM -41.8%
11MORGAN STANLEY913,893$47.2M2.4%ADD +42.9%
12GOLDMAN SACHS GROUP INC856,487$44.3M2.2%—
13BANK OF AMERICA CORP /DE/714,226$36.9M1.9%ADD +37.2%
14CHARLES SCHWAB INVESTMENT MANAGEMENT INC705,976$36.5M1.9%—
15Freestone Grove Partners LP641,319$33.1M1.7%DOUBLED +226.7%
16D. E. Shaw & Co., Inc.622,450$32.2M1.6%TRIM -27.7%
17Assenagon Asset Management S.A.530,618$27.4M1.4%NEW
18VICTORY CAPITAL MANAGEMENT INC502,406$26.0M1.3%—
19Woodline Partners LP448,996$23.2M1.2%NEW
20Pictet Asset Management Holding SA450,764$22.3M1.1%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
Point72 Asset Management, L.P.TRIM2,264,8001,318,555-41.8%$68.2M2026-Q1
BANK OF AMERICA CORP /DE/ADD520,747714,226+37.2%$36.9M2026-Q1
Freestone Grove Partners LPDOUBLED196,318641,319+226.7%$33.1M2026-Q1
Assenagon Asset Management S.A.NEW—530,618—$27.4M2026-Q1
Woodline Partners LPNEW—448,996—$23.2M2026-Q1
Nuveen, LLCADD110,790216,047+95.0%$11.2M2026-Q1
FMR LLCADD124,331209,370+68.4%$10.8M2026-Q1
Russell Investments Group, Ltd.TRIM88,07057,776-34.4%$3.0M2026-Q1
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am MainDOUBLED11,06452,809+377.3%$2.7M2026-Q1
FIRST TRUST ADVISORS LPADD29,80446,627+56.4%$2.4M2026-Q1
Allworth Financial LPDOUBLED9446,558+49429.8%$2.4M2026-Q1
EXCHANGE TRADED CONCEPTS, LLCDOUBLED17,05240,368+136.7%$2.1M2026-Q1
CAPTRUST FINANCIAL ADVISORSDOUBLED18,60340,252+116.4%$2.1M2026-Q1
FIFTH THIRD BANCORPDOUBLED35234,137+9598.0%$1.8M2026-Q1
STRS OHIOADD10,50019,800+88.6%$1.0M2026-Q1
Orion Porfolio Solutions, LLCADD11,65514,962+28.4%$773.4K2026-Q1
HighTower Advisors, LLCADD8,99514,810+64.6%$765.5K2026-Q1
Brevan Howard Capital Management LPNEAR_EXIT113,19411,695-89.7%$604.5K2026-Q1
AmundiTRIM20,95910,763-48.6%$556.3K2026-Q1
Vanguard Personalized Indexing Management, LLCADD6,6009,084+37.6%$469.6K2026-Q1
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPNEAR_EXIT183,6887,595-95.9%$392.6K2026-Q1
CAPSTONE INVESTMENT ADVISORS, LLCTRIM8,8545,498-37.9%$284.2K2026-Q1
FEDERATED HERMES, INC.ADD3,4725,059+45.7%$261.5K2026-Q1
Mirae Asset Global Investments Co., Ltd.TRIM8,0902,991-63.0%$154.6K2026-Q1
Rockefeller Capital Management L.P.DOUBLED8461,944+129.8%$100.5K2026-Q1
10 unique insiders with 50 transactions. Net insider value: -$6.5M ($0.00 bought, $6.5M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Mar 18, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOEXERCISE7,250$39.40$285.6K
Mar 18, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOSELL6,838$49.55$338.8K
Mar 17, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOEXERCISE22,750$39.40$896.4K
Mar 17, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOSELL27,710$49.95$1.4M
Mar 16, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOEXERCISE22,750$36.75$836.1K
Mar 16, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOSELL34,114$50.18$1.7M
Mar 13, 2026Khattar Jack A.President, CEOJ12,500——
Mar 13, 2026Khattar Jack A.President, CEOSELL24,138$50.09$1.2M
Mar 12, 2026Hudson Frederick M.DirectorSELL5,369$50.61$271.7K
Mar 10, 2026Horich William ToddSVP, Commercial OperationsSELL4,439$55.00$244.1K
Mar 9, 2026Mottola FrankSVP, Chief Tech. Ops. OfficerSELL1,623$53.65$87.1K
Mar 9, 2026Horich William ToddSVP, Commercial OperationsSELL4,438$54.00$239.7K
Mar 6, 2026GEMAYEL GEORGESDirectorEXERCISE7,905$25.30$200.0K
Mar 6, 2026DEC TIMOTHY CSenior Vice-President & CFOEXERCISE3,000——
Mar 6, 2026DEC TIMOTHY CSenior Vice-President & CFOTAX W/H1,433$54.73$78.4K
Mar 6, 2026Mottola FrankSVP, Chief Tech. Ops. OfficerEXERCISE3,750——
Mar 6, 2026Khattar Jack A.President, CEOEXERCISE38,640——
Mar 6, 2026Khattar Jack A.President, CEOTAX W/H16,574$54.73$907.1K
Mar 6, 2026Mottola FrankSVP, Chief Tech. Ops. OfficerTAX W/H1,793$54.73$98.1K
Mar 6, 2026GEMAYEL GEORGESDirectorSELL8,787$53.00$465.7K
Mar 6, 2026Horich William ToddSVP, Commercial OperationsEXERCISE2,625——
Mar 6, 2026Horich William ToddSVP, Commercial OperationsTAX W/H1,216$54.73$66.6K
Mar 5, 2026GEMAYEL GEORGESDirectorSELL10,000$53.71$537.1K
Feb 28, 2026Khattar Jack A.President, CEOAWARD38,640——
Feb 28, 2026DEC TIMOTHY CSenior Vice-President & CFOAWARD3,000——
Feb 28, 2026Mottola FrankSVP, Chief Tech. Ops. OfficerAWARD3,750——
Feb 25, 2026Rubin JonathanSVP, Chief Medical OfficerAWARD1,250——
Feb 25, 2026Rubin JonathanSVP, Chief Medical OfficerD1,250——
Feb 25, 2026Mottola FrankSVP, Chief Tech. Ops. OfficerAWARD1,875——
Feb 25, 2026Mottola FrankSVP, Chief Tech. Ops. OfficerD1,875——
Feb 25, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOAWARD1,250——
Feb 25, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOD1,250——
Feb 25, 2026DEC TIMOTHY CSenior Vice-President & CFOAWARD2,500——
Feb 25, 2026DEC TIMOTHY CSenior Vice-President & CFOD2,500——
Feb 24, 2026Rubin JonathanSVP, Chief Medical OfficerD1,125——
Feb 24, 2026Mottola FrankSVP, Chief Tech. Ops. OfficerAWARD1,125——
Feb 24, 2026Mottola FrankSVP, Chief Tech. Ops. OfficerD1,125——
Feb 24, 2026Barlow CarroleeDirectorD4,475——
Feb 24, 2026NEWHALL CHARLES W IIIDirectorD4,475——
Feb 24, 2026GEMAYEL GEORGESDirectorAWARD4,475——
Feb 24, 2026Barlow CarroleeDirectorAWARD4,475——
Feb 24, 2026NEWHALL CHARLES W IIIDirectorAWARD4,475——
Feb 24, 2026Hudson Frederick M.DirectorAWARD4,475——
Feb 24, 2026Hudson Frederick M.DirectorD4,475——
Feb 24, 2026DEC TIMOTHY CSenior Vice-President & CFOD1,125——
Feb 24, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOAWARD1,125——
Feb 24, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOD1,125——
Feb 24, 2026GEMAYEL GEORGESDirectorD4,475——
Feb 24, 2026DEC TIMOTHY CSenior Vice-President & CFOAWARD1,125——
Feb 24, 2026Rubin JonathanSVP, Chief Medical OfficerAWARD1,125——
8 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 6 neutral. Avg impact: 4.3/10.
NEUTRAL INST-CLUSTER 3/10
Institutional cluster for SUPN shows mixed activity in Q4 2025: three buyers (Wells Fargo, Morgan St
Jun 11, 2026
NEUTRAL 8-K 3/10
Supernus notified the CVR rights agent that Milestone 1 was achieved on March 18, 2026, triggering a
May 20, 2026
NEUTRAL 8-K 2/10
Supernus Pharmaceuticals announced it will report its Q1 2026 financial results on May 5, 2026, afte
Apr 22, 2026
NEUTRAL PRESS-RELEASE 3/10
Supernus Pharmaceuticals announced it will report Q1 2026 financial results on May 5, 2026, with a s
Apr 22, 2026
BULLISH 8-K 7/10
Supernus Pharmaceuticals completed the acquisition of NV-5138/SPN-820 assets from Navitor Pharmaceut
Apr 7, 2026
NEUTRAL CLUSTER 4/10
Two insiders at Supernus Pharmaceuticals sold shares in the past week, including a director and an S
Mar 16, 2026
NEUTRAL CLUSTER 4/10
Multiple insiders at Supernus Pharmaceuticals sold shares in the past week, including SVP William To
Mar 10, 2026
BULLISH 8-K 8/10
Supernus Pharmaceuticals reported record financial results for Q4 and full year 2025, with total rev
Feb 24, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution (last covering-analyst action Dec 2025): 83% buy across 12 analysts — 4 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.

Analyst Price Targets

Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$62.83 mean target (Dec 2025)
$55.00 Low $66.00 High
MetricValue
Current Price$44.41
Target Low$55.00
Target Mean$62.83
Target Median$64.00
Target High$66.00
# Analysts6
Recommendation— (no recent coverage)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $0.46 $0.44 $0.47 -49.8% -16.5% 1↑ 0↓ $0.2B 24.3% 2
Next Q
2026-09-30
 $0.67 $0.59 $0.75 9.7% -7.4% — $0.2B 14.3% 3
Current FY
2026-12-31
 $2.49 $2.11 $2.95 3.8% +6.3% — $0.9B 20.6% 3
Next FY
2027-12-31
 $4.34 $3.77 $4.76 74.7% +2.9% — $1.0B 17.6% 3

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.455
7d ago$0.470-0.015
30d ago$0.545-0.090
60d ago$0.540-0.085
90d ago$0.540-0.085
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Historical Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Dec 19, 2025 Stifel MAINTAIN Hold Hold

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264620083%
May 1, 20264620083%
Apr 1, 20264620083%
Mar 1, 20264620083%
Feb 1, 20264620083%
Jan 1, 20264620083%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 3, 2026
Clinical Trial
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: SPN-812 (Phase 3)
Trial: Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) Sponsor: Supernus Pharmaceuticals,
May 27, 2026
other
Supernus Pharmaceuticals to Participate in June Investor Conferences
<p align="justify">ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focus
May 6, 2026
other
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
<p align="justify">ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focus
May 5, 2026
earnings
Supernus Announces First Quarter 2026 Financial Results
<p align="justify">ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focus
May 5, 2026
earnings_calendar
SUPN Q1 2026 Earnings Scheduled — 2026-05-05
Apr 22, 2026
earnings
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
<p align="justify">ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company foc
Apr 17, 2026
Clinical Trial
Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
Phase Phase 2 — COMPLETED
Feb 27, 2026
short_interest
FTD: SUPN — 31,056 shares ($1.7M) failed to deliver
Settlement: 20260227, Price: $55.75, FTD Value: $1,731,372, SUPERNUS PHARMACEUTICALS INC C
Feb 26, 2026
short_interest
FTD: SUPN — 19,032 shares ($1.1M) failed to deliver
Settlement: 20260226, Price: $56.32, FTD Value: $1,071,882.24, SUPERNUS PHARMACEUTICALS INC C
Feb 24, 2026
earnings_calendar
SUPN Q4 2025 Earnings After Market Close — 2026-02-24